Autres langues Diamyd Medical AB

Actions

DMYD B

SE0005162880

Temps Différé Nasdaq Stockholm Autres places de cotation 12:02:35 03/05/2024			Varia. 5j.	Varia. 1 janv.
10,8 ^SEK	+0,93 %		+12,50 %	+64,38 %

12/04	L'essai de phase 3 de Diamyd® franchit une étape importante en matière de recrutement	CI
27/03	Diamyd Medical AB (publ) annonce ses résultats pour le deuxième trimestre et le semestre clos le 29 février 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Diamyd Medical Raises SEK57 Million in Rights Issue	18/04
Diamyd Medical announces final outcome in the company's rights issue	18/04
Diamyd Medical announces preliminary outcome in the company's rights issue	16/04
Recruitment milestone reached in Diamyd® Phase 3 trial	12/04
Recruitment Milestone Reaches in Diamyd® Phase 3 Trial	12/04
Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes	11/04
Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue	05/04
Diamyd Medical publishes prospectus with regards to the rights issue	28/03
Quarterly Report II 23/24	27/03
Diamyd Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	27/03
Diamyd Medical to Raise SEK114 Million Via Share Offering	19/03
The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million	18/03
Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA	29/02
Diamyd Medical to Present New Genetic Data at the ASIT Summit in Boston, MA	29/02
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment	15/02
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®	15/02
Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening	14/02
In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion	24/01
In-Depth Analysis of Diamyd Medical AB's Phase II Trial Further Supports Value of Presented Insulin Production	24/01
Quarterly Report I 23/24	24/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Diamyd Medical AB

Actions

DMYD B

SE0005162880

Autres langues

Filtres